全程IMRT和西妥昔单抗、同期顺铂化疗治疗44例局部晚期口咽癌的效果对比
2019-09-02常威刘海鸿
常威 刘海鸿


[摘要] 目的 对比全程IMRT和西妥昔单抗、同期顺铂化疗治疗44例局部晚期口咽癌的效果。方法 随机选取2013年8月—2015年8月该院局部晚期口咽癌患者44例,按先后序列号(1~44)随机分为两组:一组全程IMRT和西妥昔单抗、同期顺铂化疗治疗组(研究组,22例),一组全程IMRT和西妥昔单抗治疗组(对照组,22例),统计分析两组患者的临床疗效、3年LCR、PFS、OS、不良反应发生情况。结果 研究组患者的3年LCR、PFS、OS 90.9%(20/22)、77.3%(17/22)、86.4%(19/22)均显著高于对照组77.3%(17/22)、59.1%(13/22)、68.2%(15/22)(χ2=11.14、12.83、13.34,P<0.05)。研究组患者的0~1级痤疮/痒/皮疹发生,100.0%(22/22)显著高于对照组50.0%(11/22)(χ2=11.34,P<0.05),2级、3级痤疮/痒/皮疹发生率0、0均显著低于对照组27.3%(6/22)、22.7%(5/22)(χ2=13.28,14.45,P<0.05);0~1级血液学毒性发生率59.1%(13/22)显著低于对照组86.4%(19/22)(χ2=6.63,P<0.05),2级、3级血液学毒性发生率22.7%(5/22)、18.2%(4/22)均显著高于对照组9.1%(2/22)、4.5%(1/22)(χ2=9.21、11.01,P<0.05)。结论 全程IMRT和西妥昔单抗、同期顺铂化疗治疗局部晚期口咽癌的疗效与全程IMRT和西妥昔单抗治疗相当,更能有效提升患者的3年LCR、PFS、OS,降低患者的痤疮/痒/皮疹发生率,但会提升患者的血液学毒性发生率。
[关键词] 全程IMRT;西妥昔單抗;同期顺铂化疗;局部晚期口咽癌
[中图分类号] R739 [文献标识码] A [文章编号] 1674-0742(2019)06(a)-0132-03
[Abstract] Objective To compare the efficacy of whole course IMRT, cetuximab and cisplatin in the treatment of 44 patients with locally advanced oropharyngeal cancer. Methods A total of 44 cases of patients with locally advanced oropharyngeal cancer in our hospital from August 2013 to August 2015 were randomly selected and divided into two groups according to serial number (1-44). One group were treated with IMRT and cetuximab, cisplatin chemotherapy (study group, 22 cases), and the other group were treated with IMRT and cetuximab (control group, 22 cases). The clinical efficacy, 3-year LCR, PFS, OS and adverse reactions of the two groups were statistically analyzed. Results The LCR, PFS, OS of the study group were 90.9% (20/22), 77.3% (17/22) and 86.4% (19/22), which were significantly higher than those in the control group 77.3% (17/22), 59.1% (13/22) and 68.2% (15/22) (χ2=11.14, 12.83, 13.34, P<0.05). The incidence of acne/itch/rash of the study group 100.0% (22/22) was significantly higher than the control group 50.0% (11/22) (χ2=11.34, P<0.05). The incidence of acne/itch/rash in grade 2 and grade 3 of the study group were significantly lower than the control group 27.3% (6/22), 22.7% (5/22) (χ2=13.28, 14.45, P<0.05). And the incidence of hematological toxicity in grade 0~1 (13/22) 53.1%was significantly lower than the control group 86.4% (19/22) (χ2=6.63, P<0.05). The incidence of grade 2 and grade 3 hematological toxicity 22.7% (5/22) and 18.2% (4/22) were significantly higher than the control group 9.1% (2/22) and 4.5% (1/22) (χ2=9.21, 11.01, P<0.05). Conclusion The efficacy of whole course IMRT, cetuximab and cisplatin in the treatment of locally advanced oropharyngeal cancer is comparable to whole course IMRT and cetuximab, which can more effectively improve the 3-year LCR, PFS and OS of patients, reduce the incidence of acne/itch/rash, but will increase the incidence of hematological toxicity.
[Key words] Whole course IMRT; Cetuximab; Concurrent cisplatin chemotherapy; Locally advanced oropharyngeal cancer
口咽癌属于一种恶性肿瘤,在软腭和舌骨水平之间原发,包括会厌、扁桃体、舌根等部位,具有较高的恶性度、较快的发展速度[1],大部分患者在同步放化疗阶段会有2~3级口腔粘膜反应,对西妥昔单抗进行应用也能够将良好的生存获取过来[2]。该研究对2013年8月—2015年8月该院局部晚期口咽癌患者44例的临床资料进行了统计分析,对比了全程IMRT和西妥昔单抗、同期顺铂化疗治疗44例局部晚期口咽癌的效果,现报道如下。
1 资料与方法
1.1 一般资料
随机选取该院局部晚期口咽癌患者44例,按先后序列号(1~44)随机分为2组:一组全程IMRT和西妥昔单抗、同期顺铂化疗治疗组(研究组,22例),一组全程IMRT和西妥昔单抗治疗组(对照组,22例)。研究组患者中男性18例,女性4例,年龄35~72岁,平均(50.4±8.6)岁。在临床分期方面,9例为Ⅲ期,13例为Ⅳa期。对照组患者中男性17例,女性5例,年龄36~72岁,平均(51.1±8.6)岁。两组患者的一般资料比较差异无统计学意义(P>0.05)。该研究所选病例经过伦理委员会批准。……p>
